- Home
- NXTC vs BCDA Comparison
NXTC vs BCDA Comparison
Compare NXTC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- BCDA
- Stock Information
- Founded
- NXTC 2015
- BCDA N/A
- Country
- NXTC United States
- BCDA United States
- Employees
- NXTC N/A
- BCDA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- BCDA Health Care
- Exchange
- NXTC Nasdaq
- BCDA Nasdaq
- Market Cap
- NXTC 13.9M
- BCDA 10.1M
- IPO Year
- NXTC 2019
- BCDA N/A
- Fundamental
- Price
- NXTC $0.49
- BCDA $2.16
- Analyst Decision
- NXTC Strong Buy
- BCDA Strong Buy
- Analyst Count
- NXTC 2
- BCDA 1
- Target Price
- NXTC $3.50
- BCDA $25.00
- AVG Volume (30 Days)
- NXTC 141.9K
- BCDA 78.3K
- Earning Date
- NXTC 05-01-2025
- BCDA 05-14-2025
- Dividend Yield
- NXTC N/A
- BCDA N/A
- EPS Growth
- NXTC N/A
- BCDA N/A
- EPS
- NXTC N/A
- BCDA N/A
- Revenue
- NXTC N/A
- BCDA $3,000.00
- Revenue This Year
- NXTC N/A
- BCDA N/A
- Revenue Next Year
- NXTC N/A
- BCDA N/A
- P/E Ratio
- NXTC N/A
- BCDA N/A
- Revenue Growth
- NXTC N/A
- BCDA N/A
- 52 Week Low
- NXTC $0.22
- BCDA $1.63
- 52 Week High
- NXTC $1.82
- BCDA $5.69
- Technical
- Relative Strength Index (RSI)
- NXTC 55.20
- BCDA 46.19
- Support Level
- NXTC $0.45
- BCDA $1.80
- Resistance Level
- NXTC $0.52
- BCDA $2.92
- Average True Range (ATR)
- NXTC 0.05
- BCDA 0.23
- MACD
- NXTC 0.01
- BCDA -0.04
- Stochastic Oscillator
- NXTC 66.47
- BCDA 32.14
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).